Equities

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

603707:SHH

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)12.80
  • Today's Change-0.07 / -0.54%
  • Shares traded5.28m
  • 1 Year change+1.11%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,576304678
Total Receivables, Net1,1381,2241,074
Total Inventory4,1585,6164,894
Prepaid expenses525332
Other current assets, total3371,098251
Total current assets7,2628,2946,930
Property, plant & equipment, net1,2461,214910
Goodwill, net128125115
Intangibles, net467212200
Long term investments726226
Note receivable - long term------
Other long term assets------
Total assets9,52410,0108,217
LIABILITIES
Accounts payable538504434
Accrued expenses2958865
Notes payable/short-term debt1,5671,9601,607
Current portion long-term debt/capital leases5050.42--
Other current liabilities, total181153161
Total current liabilities3,0862,7052,266
Total long term debt5261,013481
Total debt2,5982,9732,087
Deferred income tax37401.42
Minority interest(3.47)(3.47)25
Other liabilities, total778566
Total liabilities3,7223,8392,839
SHAREHOLDERS EQUITY
Common stock1,6171,6171,244
Additional paid-in capital601604988
Retained earnings (accumulated deficit)3,5563,9303,136
Treasury stock - common(28)(33)(47)
Unrealized gain (loss)------
Other equity, total565358
Total equity5,8026,1715,378
Total liabilities & shareholders' equity9,52410,0108,217
Total common shares outstanding1,6131,6131,613
Treasury shares - common primary issue3.754.184.18
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.